Three‐year U.S. pharmacovigilance report of brodalumab. Issue 6 (5th September 2021)

• Record Type: Journal Article
• Authors: Lebwohl, Mark; Leonardi, Craig; Armstrong, April; Rawnsley, Nicole; Alexander, Binu; Goehring, Earl; Kerdel, Francisco; Jacobson, Abby
• Is Part Of: Dermatologic therapy. Volume 34:Issue 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-05
• Subjects: drug reaction -- pharmacology -- psoriasis -- quality of life -- therapy—systemic; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15105
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Brodalumab, an interleukin‐17 receptor A antagonist, is approved for treatment of moderate‐to‐severe plaque psoriasis in adults without response or with loss of response to other systemic therapies. In the United States, there is a boxed warning for brodalumab regarding suicidal ideation and behavior; however, no causal relationship between brodalumab and suicidality was established during pivotal trials. In the 2‐year pharmacovigilance data, no completed suicides or suicide attempts were reported. The most frequent adverse event (AE) was arthralgia. The safety profile of brodalumab is now being updated after 3 years of pharmacovigilance data. Here, we outline pharmacovigilance data reported to Ortho Dermatologics by patients and healthcare professionals in the United States from August 15, 2017, to August 14, 2020. Brodalumab exposure estimates were obtained by calculating the time between first and last prescription‐dispensing authorization dates. Data from 1854 patients were collected, and brodalumab exposure was estimated to be 2736 patient‐years. The most frequent AE was arthralgia (111 events; 0.04 events per patient‐year). One episode of suicide attempt was reported in a patient with a history of depression. No completed suicides were reported. There were 81 serious infections reported, none of which were fungal. Over the 3‐year period, 30 malignancies occurred in 25 patients, none of which were determined to be related to brodalumab. Three‐year pharmacovigilance data are consistent with the safety profile of brodalumab previously reported in long‐term analyses of clinical trials and the 2‐year pharmacovigilance data.